Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$1.03
$0.90
$0.65
$4.47
$6.54M0.3339,626 shs450,115 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.65
$0.74
$0.48
$2.48
$17.98M1.03790,948 shs380,014 shs
Novogen Limited stock logo
KZIA
Novogen
$12.78
$10.83
$3.54
$17.40
$21.09M2.17192,876 shs148,181 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.15
$1.18
$0.79
$45.50
$18.75M1.42.05 million shs699,644 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%+21.18%+15.86%+21.91%+14.32%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.00%-6.59%-5.91%-9.42%-5.28%
Novogen Limited stock logo
KZIA
Novogen
0.00%-6.44%-6.30%+44.73%+238.10%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+4.55%-12.21%+16.40%-88.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$1.03
$0.90
$0.65
$4.47
$6.54M0.3339,626 shs450,115 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.65
$0.74
$0.48
$2.48
$17.98M1.03790,948 shs380,014 shs
Novogen Limited stock logo
KZIA
Novogen
$12.78
$10.83
$3.54
$17.40
$21.09M2.17192,876 shs148,181 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.15
$1.18
$0.79
$45.50
$18.75M1.42.05 million shs699,644 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%+21.18%+15.86%+21.91%+14.32%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.00%-6.59%-5.91%-9.42%-5.28%
Novogen Limited stock logo
KZIA
Novogen
0.00%-6.44%-6.30%+44.73%+238.10%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%+4.55%-12.21%+16.40%-88.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
1.00
SellN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.25
Hold$5.00663.48% Upside
Novogen Limited stock logo
KZIA
Novogen
2.50
Moderate Buy$21.0064.32% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
1.71
Reduce$65.005,552.17% Upside

Current Analyst Ratings Breakdown

Latest APM, QNCX, KZIA, and CTXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
DowngradeSell (D-)Sell (E+)
5/19/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
UpgradeHold
5/18/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingBuy$4.00
5/6/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
UpgradeSell (E+)Sell (D-)
5/1/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
DowngradeSell (D-)Sell (E+)
4/21/2026
Novogen Limited stock logo
KZIA
Novogen
Reiterated RatingSell (D-)
4/15/2026
Novogen Limited stock logo
KZIA
Novogen
Initiated CoverageBuy$25.00
3/27/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingSell (E+)
3/11/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingBuy$6.00
(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K15.21N/AN/A$2.17 per share0.47
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$4.29 per shareN/A
Novogen Limited stock logo
KZIA
Novogen
$30K702.90N/AN/A($5.34) per share-2.39
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A($6.41) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$1.36MN/AN/AN/AN/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)
Novogen Limited stock logo
KZIA
Novogen
-$13.41MN/AN/AN/AN/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$83.98M-$10.62N/AN/AN/AN/A-372.88%-67.99%8/11/2026 (Estimated)

Latest APM, QNCX, KZIA, and CTXR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q2 2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.2808-$0.95-$0.6693-$0.95$10.23 million$1.67 million
5/11/2026Q1 2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$1.30-$0.59+$0.71$2.88N/AN/A
3/19/2026Q2 2026
Novogen Limited stock logo
KZIA
Novogen
N/A-$1.34N/A-$1.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Novogen Limited stock logo
KZIA
Novogen
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.78
0.78
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.58
0.16
Novogen Limited stock logo
KZIA
Novogen
N/A
2.87
N/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/A
2.92
2.92

Institutional Ownership

CompanyInstitutional Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Novogen Limited stock logo
KZIA
Novogen
30.89%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%

Insider Ownership

CompanyInsider Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
4.99%
Novogen Limited stock logo
KZIA
Novogen
1.00%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
306.35 million2.29 millionNot Optionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2027.45 million26.08 millionOptionable
Novogen Limited stock logo
KZIA
Novogen
121.65 million1.64 millionNo Data
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6016.30 million15.14 millionOptionable

Recent News About These Companies

Quince Therapeutics Delays Annual 10-K Filing
Bankruptcy threat looms as Quince runs out of options

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptorum Group stock logo

Aptorum Group NASDAQ:APM

$1.03 0.00 (0.00%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+2.43%)
As of 07:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$0.65 0.00 (0.00%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$0.65 0.00 (-0.29%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Novogen stock logo

Novogen NASDAQ:KZIA

$12.78 0.00 (0.00%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$12.78 0.00 (-0.04%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.15 0.00 (0.00%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$1.17 +0.02 (+1.74%)
As of 07:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.